2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Lymphoma
2
Leukemia, Myeloid, Acute
2
Carcinoma, Non-Small-Cell Lung
2
Triple Negative Breast Neoplasms
1
Smoldering Multiple Myeloma
1
Sarcoma
1
Myelodysplastic Syndromes
1
Metastasis From Malignant Tumor of Kidney (Disorder)
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Lung Neoplasms
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Breast Neoplasms
1
Interventions
Cyclophosphamide
211
fludarabine phosphate
185
Azacitidine
160
fludarabine
144
Busulfan
140
Tacrolimus
120
Mycophenolic Acid
112
Cytarabine
111
Whole-Body Irradiation
107
Peripheral Blood Stem Cell Transplantation
99
Antilymphocyte Serum
97
Melphalan
91
Filgrastim
87
Cyclosporine
83
Decitabine
82
Methotrexate
79
venetoclax
63
Granulocyte Colony-Stimulating Factor
56
Radiotherapy
49
Stem Cell Transplantation
48
Thiotepa
47
Cord Blood Stem Cell Transplantation
43
Clofarabine
42
thymoglobulin
41
Specimen Handling
35
Etoposide
35
Methylprednisolone
34
Sirolimus
33
Biopsy
30
Injections
27
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Myelodysplastic Syndromes
×
Immunotherapy, Active
×
Clear all
NCT01819558
2015-03-20
ALLO-WT1
Institut Paoli-Calmettes
Phase 1/2
Completed
2 enrolled